APPROACH AND TREATMENT OF NON-MELANOMA SKIN CANCER DURING PREGNANCY
PDF

Palavras-chave

non-melanoma skin cancer, pregnancy, treatment, approach and fetal safety

Como Citar

Miserani , M. T. C. L. de C., Cintra , G. da S., Oliani , A. L. G., Silva , S. P. S., Pinto , L. R., Novaes Narde, E., Salewski, I., Carvalho , S. F. de A., Souza , A. M. F. B. de, Melo , L. D., Braga , J. P. N., Vilela , L. F., Orsiolli , C. A. G., & Silva , K. R. da. (2024). APPROACH AND TREATMENT OF NON-MELANOMA SKIN CANCER DURING PREGNANCY. Brazilian Journal of Implantology and Health Sciences, 6(4), 1705–1716. https://doi.org/10.36557/2674-8169.2024v6n4p1705-1716

Resumo

Pregnancy presents unique challenges in diagnosing and treating non-melanoma skin cancer, the most common type of skin cancer. Hormonal and immunological changes during pregnancy can influence the development and progression of the disease, while ethical issues and concerns about fetal safety complicate the therapeutic approach. Therefore, it is crucial to understand how this condition is managed during pregnancy to ensure the best outcome for mother and baby. Objective: The objective of this systematic literature review is to analyze the approaches and treatments used for non-melanoma skin cancer during pregnancy, with a focus on maternal and fetal safety. Methodology: The review followed the PRISMA checklist guidelines. Articles published in the last 10 years were searched in the PubMed, Scielo and Web of Science databases. The descriptors used were "non-melanoma skin cancer", "pregnancy", "treatment", "approach" and "fetal safety". The inclusion criteria were studies that described cases of non-melanoma skin cancer during pregnancy, addressing treatment options and fetal safety considerations. The exclusion criteria were studies irrelevant to the topic, studies without access to the full text and studies not available in English, Portuguese or Spanish. Results: Analysis of the articles revealed several therapeutic approaches for non-melanoma skin cancer during pregnancy, including surgery, photodynamic therapy and cryotherapy. There was an emphasis on the individualized assessment of each case, taking into account the stage of the disease, the location of the tumor and the potential risks for the mother and fetus. Prevention was also highlighted, with an emphasis on sun protection and skin self-examination. However, some treatments have been delayed until after birth due to concerns about fetal safety. Conclusion: The management of non-melanoma skin cancer during pregnancy requires a multidisciplinary and individualized approach, considering the risks and benefits for the mother and fetus. Prevention, early diagnosis and adequate treatment are essential to guarantee the best result for both. More research is needed to further guide clinical practices in this area.

https://doi.org/10.36557/2674-8169.2024v6n4p1705-1716
PDF

Referências

Amado J, Oliveira M, Velho GC, Costa V, Torres FO, Massa A. Skin cancer. Acta Med Port . 1998;11(6):529-532.

Melanda VS, Galiciolli MEA, Lima LS, Figueiredo BC, Oliveira CS. Impact of Pesticides on Cancer and Congenital Malformation: A Systematic Review. Toxics . 2022;10(11):676. Published 2022 Nov 9. doi:10.3390/toxics10110676

Silva MMJ, Nogueira DA, Clapis MJ, Leite EPRC. Anxiety in pregnancy: prevalence and associated factors. Rev Esc Enferm USP . 2017;51:e03253. Published 2017 Aug 28. doi:10.1590/S1980-220X2016048003253

Roy PS, Saikia BJ. Cancer and cure: A critical analysis. Indian J Cancer . 2016;53(3):441-442. doi:10.4103/0019-509X.200658

Hausman DM. What Is Cancer? Perspect Biol Med . 2019;62(4):778-784. doi:10.1353/pbm.2019.0046

Raghani NR, Chorawala MR, Mahadik M, Patel RB, Prajapati BG, Parekh PS. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies. Med Oncol . 2024;41(2):51. Published 2024 Jan 9. doi:10.1007/s12032-023-02280-7

Chhikara BS, Parang K. Global Cancer Statistics 2022: The Trend Projection Analysis. Chemistry Biol Lett. 2022;10(1):451.

Hausmann DM. What is cancer? Biol Med Perspective 2019;62(4):778–84. -PubMed - DOI

Hoos A. Immuno-oncology drug development - from CTLA4 to PD1 for next generations. Nat Rev Drug Discov. 2016;15(4):235–47. -PubMed - DOI

Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev . 2016;25(1):16-27. doi:10.1158/1055-9965.EPI-15-0578

Dolgin E. Cancer's new normal [published correction appears in Nat Cancer. 2022 Mar;3(3):372]. Nat Cancer . 2021;2(12):1248-1250. doi:10.1038/s43018-021-00304-7

Mullard A. Addressing cancer's grand challenges. Nat Rev Drug Discov . 2020;19(12):825-826. doi:10.1038/d41573-020-00202-0

Graham TA, Sottoriva A. Measuring cancer evolution from the genome. J Pathol . 2017;241(2):183-191. doi:10.1002/path.4821

Zaimy MA, Saffarzadeh N, Mohammadi A, et al. New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther . 2017;24(6):233-243. doi:10.1038/cgt.2017.16

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Copyright (c) 2024 Maria Thereza Costa Lima de Castro Miserani , Guilherme da Silveira Cintra , Ana Lara Gimenes Oliani , Stefane Paula Souza Silva , Luiza Ribeiro Pinto , Elisangela Novaes , Isabella Salewski, Sílvio Francisco de Almeida Carvalho , Aline Morais Fontenele Barboza de Souza , Laura Diogo Melo , Jessica Portes Nico Braga , Livia Fagundes Vilela , Camila Alessandra Grando Orsiolli , Karolayne Ribeiro da Silva

Downloads

Não há dados estatísticos.